Arca BioPharma hopeful about personalized beta blocker

07/28/2008 | American City Business Journals

Arca BioPharma is inching closer to launching bucindolol, an experimental beta blocker that would be the first genetically targeted heart-failure drug. The biotech firm intends to file this week for FDA approval of the drug along with a genetic test being developed by partner Lab Corp.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY